Company / Working Capital
BioMarin Pharmaceutical Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$3.2B
FY2025
5-year range
$1.7B / $3.2B
FY2021-FY2025
Trend
+21.7%
vs FY2024
Sector context
#14 of 213
Health Care
What the data says
Among 213 Health Care companies, BioMarin Pharmaceutical is in the top 7% for working capital. Working Capital has fluctuated over the past 10 years, ranging from $982M in FY2016 to $3.2B in FY2025.
Based on SEC 10-K filings.
$3.2B in FY2025 with a 5-year CAGR of +11.5%. Top quartile in the Health Care sector.
Improved from $1.8B to $3.2B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +13.9%
- 5-Year CAGR
- +11.5%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 213This company $3.2B Sector average $934.6M
▼
+241.8% above sector average
Key checks
Key Insights
- 5-year CAGR of +11.5%, indicating consistent growth.
- In FY2025, working capital increased 21.7% year-over-year.
- Ranks #14 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.2B | +21.7% |
| FY2024 | $2.6B | +47.6% |
| FY2023 | $1.8B | -17.7% |
| FY2022 | $2.2B | +25.2% |
| FY2021 | $1.7B | -6.6% |
| FY2020 | $1.8B | +83.2% |
| FY2019 | $1.0B | -34.1% |
| FY2018 | $1.5B | +10.2% |
| FY2017 | $1.4B | +41.5% |
| FY2016 | $982.5M | +52.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026